{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:15:59Z","timestamp":1760120159178},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T00:00:00Z","timestamp":1466035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T00:00:00Z","timestamp":1466035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycystic ovary syndrome (PCOS) is a common multifactorial endocrine disorder among women of childbearing age. PCOS has various and heterogeneous clinical features apart from its indefinite pathogenesis and mechanism. Clinical drugs for PCOS are multifarious because it only treats separate symptoms. Berberine is an isoquinoline plant alkaloid with numerous biological activities, and it was testified to improve some diseases related to PCOS in animal models and in humans. Systems pharmacology was utilized to predict the potential targets of berberine related to PCOS and the potential drug-drug interaction base on the disease network. In conclusion, berberine is a promising polypharmacological drug for treating PCOS, and for enhancing the efficacy of clinical drugs.<\/jats:p>","DOI":"10.1038\/srep28089","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T10:07:14Z","timestamp":1466071634000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome"],"prefix":"10.1038","volume":"6","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixue","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,16]]},"reference":[{"key":"BFsrep28089_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0140-6736(99)00218-4","volume":"354","author":"A Balen","year":"1999","unstructured":"Balen, A. Pathogenesis of polycystic ovary syndrome\u2013the enigma unravels? Lancet 354, 966\u2013967 (1999).","journal-title":"Lancet"},{"key":"BFsrep28089_CR2","doi-asserted-by":"publisher","first-page":"s101","DOI":"10.1016\/S0002-9378(98)70240-6","volume":"179","author":"RS Legro","year":"1998","unstructured":"Legro, R. S. Polycystic ovary syndrome: current and future treatment paradigms. Am J Obstet Gynecol 179, s101\u2013s108 (1998).","journal-title":"Am J Obstet Gynecol"},{"key":"BFsrep28089_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(07)61345-2","volume":"370","author":"RJ Norman","year":"2007","unstructured":"Norman, R. J., Dewailly, D., Legro, R. S. & Hickey, T. E. Polycystic ovary syndrome. Lancet 370, 685\u2013697 (2007).","journal-title":"Lancet"},{"key":"BFsrep28089_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000277640","volume":"69","author":"C Moran","year":"2010","unstructured":"Moran, C. et al. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest 69, 274\u2013280 (2010).","journal-title":"Gynecol Obstet Invest"},{"key":"BFsrep28089_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/humrep\/des028","volume":"27","author":"R Sanchon","year":"2012","unstructured":"Sanchon, R. et al. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum Reprod 27, 1209\u20131216 (2012).","journal-title":"Hum Reprod"},{"key":"BFsrep28089_CR6","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro, R. S. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98, 4565\u20134592 (2013).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep28089_CR7","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1517\/14656566.2015.1047344","volume":"16","author":"ML Rocca","year":"2015","unstructured":"Rocca, M. L. et al. Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opin Pharmacother 16, 1369\u20131393 (2015).","journal-title":"Expert Opin Pharmacother"},{"key":"BFsrep28089_CR8","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz, R. et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91, 4237\u20134245 (2006).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep28089_CR9","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1210\/jc.2006-2725","volume":"92","author":"E Carmina","year":"2007","unstructured":"Carmina, E. et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92, 2500\u20132505 (2007).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep28089_CR10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1210\/jc.2012-3698","volume":"98","author":"S Borruel","year":"2013","unstructured":"Borruel, S. et al. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 98, 1254\u20131263 (2013).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep28089_CR11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/j.1464-5491.2011.03460.x","volume":"28","author":"JM Pauli","year":"2011","unstructured":"Pauli, J. M., Raja-Khan, N., Wu, X. & Legro, R. S. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med 28, 1445\u20131454 (2011).","journal-title":"Diabet Med"},{"key":"BFsrep28089_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/sj.ijo.0801994","volume":"26","author":"A Gambineri","year":"2002","unstructured":"Gambineri, A., Pelusi, C., Vicennati, V., Pagotto, U. & Pasquali, R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26, 883\u2013896 (2002).","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFsrep28089_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.tem.2007.07.003","volume":"18","author":"HF Escobar-Morreale","year":"2007","unstructured":"Escobar-Morreale, H. F. & San Millan, J. L. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 18, 266\u2013272 (2007).","journal-title":"Trends Endocrinol Metab"},{"key":"BFsrep28089_CR14","first-page":"CD007506","volume":"7","author":"LJ Moran","year":"2011","unstructured":"Moran, L. J., Hutchison, S. K., Norman, R. J. & Teede, H. J. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 7, CD007506 (2011).","journal-title":"Cochrane Database Syst Rev"},{"key":"BFsrep28089_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ptr.2399","volume":"22","author":"M Imanshahidi","year":"2008","unstructured":"Imanshahidi, M. & Hosseinzadeh, H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 22, 999\u20131012 (2008).","journal-title":"Phytother Res"},{"key":"BFsrep28089_CR16","doi-asserted-by":"publisher","first-page":"S197","DOI":"10.1016\/j.fertnstert.2010.07.764","volume":"94","author":"X Wu","year":"2010","unstructured":"Wu, X. Theca insulin resistance: dexamethasone induction and berberine intervention. Fertil Steril 94, S197 (2010).","journal-title":"Fertil Steril"},{"key":"BFsrep28089_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.fertnstert.2010.07.1090","volume":"95","author":"L Zhao","year":"2011","unstructured":"Zhao, L. et al. Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro . Fertil Steril 95, 461\u2013463 (2011).","journal-title":"Fertil Steril"},{"key":"BFsrep28089_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/EJE-11-0616","volume":"166","author":"W Wei","year":"2012","unstructured":"Wei, W. et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol 166, 99\u2013105 (2012).","journal-title":"Eur J Endocrinol"},{"key":"BFsrep28089_CR19","doi-asserted-by":"publisher","first-page":"e003934","DOI":"10.1136\/bmjopen-2013-003934","volume":"3","author":"Y Li","year":"2013","unstructured":"Li, Y. et al. Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial. BMJ open 3, e003934 (2013).","journal-title":"BMJ open"},{"key":"BFsrep28089_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cen.12294","volume":"80","author":"Y An","year":"2014","unstructured":"An, Y. et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol 80, 425\u2013431 (2014).","journal-title":"Clin Endocrinol"},{"key":"BFsrep28089_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/1745-6215-14-226","volume":"14","author":"Y Li","year":"2013","unstructured":"Li, Y. et al. Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial. Trials 14, 226 (2013).","journal-title":"Trials"},{"key":"BFsrep28089_CR22","doi-asserted-by":"publisher","first-page":"e0144072","DOI":"10.1371\/journal.pone.0144072","volume":"10","author":"L Li","year":"2015","unstructured":"Li, L. et al. A Single Arm Pilot Study of Effects of Berberine on the Menstrual Pattern, Ovulation Rate, Hormonal and Metabolic Profiles in Anovulatory Chinese Women with Polycystic Ovary Syndrome. PloS one 10, e0144072 (2015).","journal-title":"PloS one"},{"key":"BFsrep28089_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s12272-014-0510-6","volume":"38","author":"M Kwon","year":"2015","unstructured":"Kwon, M., Choi, Y. A., Choi, M.-K. & Song, I.-S. Organic cation transporter-mediated drug\u2013drug interaction potential between berberine and metformin. Arch Pharm Res 38, 849\u2013856 (2015).","journal-title":"Arch Pharm Res"},{"key":"BFsrep28089_CR24","doi-asserted-by":"publisher","first-page":"145325","DOI":"10.1155\/2014\/145325","volume":"2014","author":"D Colombo","year":"2014","unstructured":"Colombo, D., Lunardon, L. & Bellia, G. Cyclosporine and herbal supplement interactions. J Toxicol 2014, 145325 (2014).","journal-title":"J Toxicol"},{"key":"BFsrep28089_CR25","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00228-013-1537-1","volume":"69","author":"Q Hou","year":"2013","unstructured":"Hou, Q., Han, W. & Fu, X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol 69, 1861\u20131862 (2013).","journal-title":"Eur J Clin Pharmacol"},{"key":"BFsrep28089_CR26","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/S0140-6736(15)00651-0","volume":"386","author":"X-K Wu","year":"2015","unstructured":"Wu, X.-K. et al. Letrozole, berberine, or a combination for infertility in Chinese women with polycystic ovary syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386, S70 (2015).","journal-title":"Lancet"},{"key":"BFsrep28089_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2015.09.032","volume":"243","author":"A Pirillo","year":"2015","unstructured":"Pirillo, A. & Catapano, A. L. Berberine, a plant alkaloid with lipid-and glucose-lowering properties: From in vitro evidence to clinical studies. Atherosclerosis 243, 449\u2013461 (2015).","journal-title":"Atherosclerosis"},{"key":"BFsrep28089_CR28","unstructured":"Sorger, P. K. et al. In An NIH white paper by the QSP workshop group. 1\u201348 (NIH Bethesda, 2011)."},{"key":"BFsrep28089_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/minf.200900081","volume":"29","author":"D Rognan","year":"2010","unstructured":"Rognan, D. Structure\u2010based approaches to target fishing and ligand profiling. Mol Inform 29, 176\u2013187 (2010).","journal-title":"Mol Inform"},{"key":"BFsrep28089_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tibtech.2008.09.005","volume":"27","author":"G Schneider","year":"2009","unstructured":"Schneider, G. et al. Voyages to the (un) known: adaptive design of bioactive compounds. Trends Biotechnol 27, 18\u201326 (2009).","journal-title":"Trends Biotechnol"},{"key":"BFsrep28089_CR31","doi-asserted-by":"publisher","first-page":"15290","DOI":"10.1038\/srep15290","volume":"5","author":"J Li","year":"2015","unstructured":"Li, J., Zhao, P., Li, Y., Tian, Y. & Wang, Y. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease. Sci Rep 5, 15290 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep28089_CR32","doi-asserted-by":"publisher","first-page":"17646","DOI":"10.1038\/srep17646","volume":"5","author":"W Nie","year":"2015","unstructured":"Nie, W., Lv, Y., Yan, L., Chen, X. & Lv, H. Prediction and Characterisation of the System Effects of Aristolochic Acid: A Novel Joint Network Analysis towards Therapeutic and Toxicological Mechanisms. Sci Rep 5, 17646 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep28089_CR33","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.fertnstert.2011.03.021","volume":"95","author":"J Bellver","year":"2011","unstructured":"Bellver, J. et al. Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. Fertil Steril 95, 2335\u20132341, e2338 (2011).","journal-title":"Fertil Steril"},{"key":"BFsrep28089_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s001090050063","volume":"74","author":"A Whitmarsh","year":"1996","unstructured":"Whitmarsh, A. & Davis, R. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74, 589\u2013607 (1996).","journal-title":"J Mol Med"},{"key":"BFsrep28089_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/me.2004-0178","volume":"19","author":"VL Nelson-Degrave","year":"2005","unstructured":"Nelson-Degrave, V. L. et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol 19, 379\u2013390 (2005).","journal-title":"Mol Endocrinol"},{"key":"BFsrep28089_CR36","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"Diamanti-Kandarakis, E. & Dunaif, A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33, 981\u20131030 (2012).","journal-title":"Endocr Rev"},{"key":"BFsrep28089_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091\u20131093 (2009).","journal-title":"Bioinformatics"},{"key":"BFsrep28089_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/humupd\/dmi005","volume":"11","author":"J Vrbikova","year":"2005","unstructured":"Vrbikova, J. & Cibula, D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11, 277\u2013291 (2005).","journal-title":"Hum Reprod Update"},{"key":"BFsrep28089_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.fertnstert.2006.11.137","volume":"88","author":"V De Leo","year":"2007","unstructured":"De Leo, V. et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril 88, 113\u2013117 (2007).","journal-title":"Fertil Steril"},{"key":"BFsrep28089_CR40","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1530\/EJE-13-0585","volume":"170","author":"R Pasquali","year":"2014","unstructured":"Pasquali, R. & Gambineri, A. THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome. Eur J Endocrinol 170, R75\u2013R90 (2014).","journal-title":"Eur J Endocrinol"},{"key":"BFsrep28089_CR41","first-page":"CD008565","volume":"10","author":"AD Raval","year":"2011","unstructured":"Raval, A. D., Hunter, T., Stuckey, B. & Hart, R. J. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 10, CD008565 (2011).","journal-title":"J. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev"},{"key":"BFsrep28089_CR42","first-page":"1","volume":"6","author":"SM Sirmans","year":"2014","unstructured":"Sirmans, S. M. & Pate, K. A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 6, 1 (2014).","journal-title":"Clin Epidemiol"},{"key":"BFsrep28089_CR43","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.1038\/srep10132","volume":"5","author":"SS Udhane","year":"2015","unstructured":"Udhane, S. S., Pandey, A. V., Hofer, G., Mullis, P. E. & Fl\u00fcck, C. E. Retinoic acid receptor beta and angiopoietin-like protein 1 are involved in the regulation of human androgen biosynthesis. Sci Rep 5, 10132 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep28089_CR44","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4158\/EP12303.RA","volume":"19","author":"JA Davidson","year":"2013","unstructured":"Davidson, J. A. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract 19, 1050 (2013).","journal-title":"Endocr Pract"},{"key":"BFsrep28089_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EJE-11-0091","volume":"165","author":"A Gambineri","year":"2011","unstructured":"Gambineri, A. et al. A combination of polymorphisms in HSD11B1 associates with in vivo 11\u03b2-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur J Endocrinol 165, 283\u2013292 (2011).","journal-title":"Eur J Endocrinol"},{"key":"BFsrep28089_CR46","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/oby.20356","volume":"21","author":"T Hughes","year":"2013","unstructured":"Hughes, T. et al. Ascending dose\u2010controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity 21, 1782\u20131788 (2013).","journal-title":"Obesity"},{"key":"BFsrep28089_CR47","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.2337\/diabetes.54.11.3296","volume":"54","author":"NJ Spencer-Jones","year":"2005","unstructured":"Spencer-Jones, N. J. et al. Protein tyrosine phosphatase-1B gene PTPN1: selection of tagging single nucleotide polymorphisms and association with body fat, insulin sensitivity, and the metabolic syndrome in a normal female population. Diabetes 54, 3296\u20133304 (2005).","journal-title":"Diabetes"},{"key":"BFsrep28089_CR48","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrd2830","volume":"8","author":"JD Baxter","year":"2009","unstructured":"Baxter, J. D. & Webb, P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8, 308\u2013320 (2009).","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep28089_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s001250051120","volume":"42","author":"S Ishiyama-Shigemoto","year":"1999","unstructured":"Ishiyama-Shigemoto, S., Yamada, K., Yuan, X., Ichikawa, F. & Nonaka, K. Association of polymorphisms in the \u03b22-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia 42, 98\u2013101 (1999).","journal-title":"Diabetologia"},{"key":"BFsrep28089_CR50","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1124\/mol.114.095810","volume":"87","author":"S Krishan","year":"2015","unstructured":"Krishan, S., Richardson, D. R. & Sahni, S. Adenosine Monophosphate\u2013Activated Kinase and Its Key Role in Catabolism: Structure, Regulation, Biological Activity, and Pharmacological Activation. Mol Pharmacol 87, 363\u2013377 (2015).","journal-title":"Mol Pharmacol"},{"key":"BFsrep28089_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","volume":"492","author":"J Besnard","year":"2012","unstructured":"Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215\u2013220 (2012).","journal-title":"Nature"},{"key":"BFsrep28089_CR52","doi-asserted-by":"crossref","unstructured":"Yang, H. et al. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic acids res. gkv1230 (2015).","DOI":"10.1093\/nar\/gkv1230"},{"key":"BFsrep28089_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2217\/pgs.10.15","volume":"11","author":"CF Thorn","year":"2010","unstructured":"Thorn, C. F., Klein, T. E. & Altman, R. B. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 11, 501\u2013505 (2010).","journal-title":"Pharmacogenomics"},{"key":"BFsrep28089_CR54","doi-asserted-by":"publisher","first-page":"D514","DOI":"10.1093\/nar\/gki033","volume":"33","author":"A Hamosh","year":"2005","unstructured":"Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A. & McKusick, V. A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33, D514\u2013D517 (2005).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep28089_CR55","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro, R. S. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98, 4565\u20134592 (2013).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep28089_CR56","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart, D. S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34, D668\u2013D672 (2006).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep28089_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1758-2946-3-32","volume":"3","author":"E Bolton","year":"2011","unstructured":"Bolton, E. et al. PubChem3D: a new resource for scientists. J Cheminform 3, 32 (2011).","journal-title":"J Cheminform"},{"key":"BFsrep28089_CR58","doi-asserted-by":"publisher","first-page":"W609","DOI":"10.1093\/nar\/gkq300","volume":"38","author":"X Liu","year":"2010","unstructured":"Liu, X. et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res 38, W609\u2013W614 (2010).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep28089_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1758-2946-6-13","volume":"6","author":"J Ru","year":"2014","unstructured":"Ru, J. et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 6, 13 (2014).","journal-title":"J Cheminform"},{"key":"BFsrep28089_CR60","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2008","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44\u201357 (2008).","journal-title":"Nat Protoc"},{"key":"BFsrep28089_CR61","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498\u20132504 (2003).","journal-title":"Genome Res"},{"key":"BFsrep28089_CR62","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455\u2013461 (2010).","journal-title":"J Comput Chem"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep28089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28089","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T17:38:33Z","timestamp":1718645913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep28089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,16]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,6,27]]}},"alternative-id":["BFsrep28089"],"URL":"https:\/\/doi.org\/10.1038\/srep28089","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,16]]},"assertion":[{"value":"3 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28089"}}